Ligand validation:7X86

A3I: (4S,4aS,6aR,8R,9R,10aS,13S,14aS,18aR,18bR,E)-9-ethyl-4,8,19-trihydroxy-10a,12,13,18a-tetramethyl-2,3,4,4a,6a,7,8,9,10,10a,13,14,18a,18b-tetradecahydro-14a,17-(metheno)benzo[b]naphtho[2,1-h][1]azacyclododecine-16,18(1H,15H)-dione

A3I is a Ligand Of Interest in 7X86 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7X86_A3I_B_201	46%	4%	0.191	0.926	4.13	1.65	14	7	0	0	100%	1
7X86_A3I_A_201	40%	4%	0.196	0.909	4.1	1.67	14	6	0	0	100%	1
7X86_A3I_D_201	30%	4%	0.227	0.893	4.12	1.73	15	9	0	0	100%	1
7X86_A3I_C_201	23%	4%	0.238	0.863	4.16	1.57	15	8	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.